Newsbot

Shell Aktie: Aktualisierung des Basisszenarios macht Revision der Empfehlung notwendig

Wien (www.aktiencheck.de) - Shell-Aktienanalyse der Raiffeisen Bank International AG (RBI):Aaron Alber, Analyst der Raiffeisen Bank International AG (RBI), rät in einer aktuellen Aktienanalyse zum Kauf der Aktie von Shell plc (ISIN: GB00BP6MXD84, WKN: A3C99G, Ticker-Symbol: R6C0, London Stock Exchange-Symbol: SHEL). [mehr]

Equinor Aktie: Anpassung der Empfehlung an neues Ölpreisszenario

Wien (www.aktiencheck.de) - Equinor-Aktienanalyse der Raiffeisen Bank International AG:Aaron Alber, Analyst der Raiffeisen Bank International AG (RBI), rät in einer aktuellen Aktienanalyse zum Kauf der Aktie der Equinor ASA (ISIN: NO0010096985, WKN: 675213, Ticker-Symbol: DNQ, Euronext Oslo-Symbol: EQNR, NASDAQ OTC-Symbol: STOHF). [mehr]
Nike

Nike Aktie: Warum jetzt vor allem das Auslandsgeschäft Sorgen macht

San Francisco (www.aktiencheck.de) - Nike-Aktienanalyse von Wells Fargo:Der Wells-Fargo-Analyst Ike Boruchow habe das Kursziel für die Aktie von Nike Inc. (ISIN: US6541061031, WKN: 866993, Ticker-Symbol: NKE, NYSE-Symbol: NKE) von 65 auf 55 USD gesenkt und das "overweight"-Rating beibehalten. Mit Blick auf das Quartal erkläre er, dass die negativen Aspekte die positiven überwogen hätten. [mehr]

Visa: Warum die Aktie für geduldige Anleger jetzt trotzdem spannend wird

New York (www.aktiencheck.de) - Visa-Aktienanalyse von Evercore ISI:Evercore ISI habe das Kursziel für die Aktie von Visa Inc. (ISIN: US92826C8394, WKN: A0NC7B, Ticker-Symbol: 3V64, NYSE-Symbol: V) von 380 auf 340 USD gesenkt und das "in line"-Rating beibehalten. Visa und MasterCard würden zwar weiterhin eine starke langfristige Qualität bieten, doch die Skepsis der Investoren nehme zu, da sich der Markt zunehmend von der kurzfristigen operativen Entwicklung ab- und stattdessen dem langfristig...

Eli Lilly Aktie: Was BMO Capital jetzt sieht, das viele Anleger noch unterschätzen

Bad Marienberg (www.aktiencheck.de) - Eli Lilly: BMO Capital bleibt bei "outperform" – und das Kursziel 1.300 USD leuchtet weiter wie ein Börsen-ScheinwerferWenn eine Aktienanalyse von BMO Capital bei Eli Lilly auf dem Tisch landet, hört der Markt hin. Und diesmal ganz besonders. Denn BMO Capital hat am 01.04.2026 das Rating "outperform" für Eli Lilly bestätigt und das Kursziel 1.300 USD unverändert stehen lassen. [mehr]

3M Aktie: Wells Fargo bleibt bullish, kappt aber das Kursziel

Bad Marienberg (www.aktiencheck.de) - 3M: Was Wells Fargo jetzt wirklich an der Aktie überzeugt - und was nichtDie neue Aktienanalyse von Wells Fargo Aktie zu 3M Company (ISIN: US88579Y1010, WKN: 851745, Ticker-Symbol: MMM, NYSE-Symbol: MMM) hat das Zeug zum Gesprächsstoff auf jedem Börsenparkett: Wells Fargo bestätigt für 3M das Rating "overweight", senkt aber zugleich das Kursziel auf 160 USD von zuvor 175 USD. [mehr]

DRVN INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Driven Brands Holdings Inc. Investors

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds Driven Brands Holdings Inc. (“Driven Brands” or the “Company”) (NASDAQ:DRVN) investors of the May 8, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Driven Brands securities between May 9, 2023 through February 24, 2026 (“the Class Period”).

TruBridge Investor News: If You Have Suffered Losses in TruBridge, Inc. (NASDAQ: TBRG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TruBridge, Inc. (NASDAQ: TBRG) resulting from allegations that TruBridge, Inc. may have issued materially misleading business information to the investing public.

Crypto News: AlphaPepe Stage 10 Nearly Sold Out Prior Big Price Rise As XRP Eyes $5 Breakout

MONACO, April 03, 2026 (GLOBE NEWSWIRE) -- AlphaPepe Stage 10 is nearly sold out and the next stage brings a significant price increase. Capital is entering at a pace that draws direct comparisons to the earliest days of meme coins that went on to deliver life changing returns to early participants. The crypto news around AlphaPepe is building ahead of a planned Q2 2026 exchange listing, stages are closing faster with each round, and wallets are committing serious size while XRP sits at $1.32 ...

Male Aesthetics Spending Fuels A Multibillion-Dollar Medspa Land Grab

Men are driving the next wave of medspa growth - from Botox to body contouring - as private equity races to consolidate a fragmented, $78 billion global market. Find out which funds are betting on male aesthetics and why the biggest opportunity may still be untapped.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages New Era Energy & Digital, Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – NUAI

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of New Era Energy & Digital, Inc. (NASDAQ: NUAI) between November 6, 2024 and December 29, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2026.
COTY

COTY SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Coty Inc. Investors - Contact Kirby McInerney LLP by May 22, 2026

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Coty Inc. (“Coty” or the “Company”) (NYSE:COTY) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2....

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended,...

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders

LAS VEGAS, NEVADA., April 03, 2026 (GLOBE NEWSWIRE) -- Jena Acquisition Corporation II (the “Company”) announced today that on April 1, 2026, the Company received a written notice from the staff of NYSE Regulation of the New York Stock Exchange (“NYSE”) indicating that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual (the “Listing Rule”) which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis.

Barclays Investor News: If You Have Suffered Losses in Barclays PLC (NYSE: BCS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., April 3, 2026. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS) resulting from allegations that Barclays PLC may have issued materially misleading business information to the investing public.

Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23

EFFINGHAM, Ill., April 03, 2026 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) announced today that it will issue its first quarter 2026 financial results after market close on Thursday, April 23, 2026. Along with the press release announcing the financial results, the Company will publish an investor presentation that will be available on the Webcasts and Presentations page of its investor relations website.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

AIOS Tech Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

HONG KONG, April 03, 2026 (GLOBE NEWSWIRE) -- AIOS Tech Inc. (NASDAQ: AIOS) (the “Company”), today announced that, on April 1, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the Class A Common Shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirements of Nasdaq under Nasdaq Listing Rules 5550(...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2026 (the “Grant Date”), ORIC granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to one new non-executive employee who began their employment with ORIC in March 2026.

FAR AI Opens Node Registrations, Giving GPU Owners a New Way to Earn From AI Demand

ABU DHAB?, United Arab Emirates, April 03, 2026 (GLOBE NEWSWIRE) -- FAR Labs, an AI native lab building infrastructure, AI as Service (AIaS) and physical AI systems powered by Dizzaract, announced today that its FAR AI has moved into closed testing with selected partners after completing its core development. The company is also opening node registrations, with early registrants set to receive priority onboarding when approved operators come online.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Companys 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencem...

RCM Technologies, Inc. Announces Fourth Quarter And Fiscal Year 2025 Results

PENNSAUKEN, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty healthcare, and information technology services, today announced financial results for the fourteen and fifty-three weeks ended January 3, 2026.